丙型肝炎失代偿期肝硬化患者的抗病毒治疗和长期临床结局分析

摘要

Objective To analyze the antiviral treatment and long-term clinical outcomes of patients with hepatitis c de-compensated cirrhosis. Methods The clinical data of 100 cases of patients with hepatitis c decompensated cirrhosis admit-ted and treated in our hospital from September 2014 to September 2015 were retrospectively analyzed, and the treatment was from small-dose interferon to the PEG-IFNα-2a or PEG-IFNα-2b combined with ribavirin by the gradually increasing dosage, and the response of virology of patients was evaluated, including recurrence, SVR and no response. Results The de-compensated rate of hepatic function in the SVR group was lower than that in the recurrence group and the no response group, [(14.29%(5/35) vs 31.25%(10/32) vs 78.79%(26/33)], and the blood platelet counts in the recurrence group and the SVR group increased, P<0.05. Conclusion The gradually increasing dosage of small-dose interferon and combined treat-ment with ribavirin for patients with hepatitis c decompensated cirrhosis can obtain a good clinical outcome.%目的：分析丙型肝炎失代偿期肝硬化患者抗病毒治疗与长期临床结局。方法随机选取该院2014年9月—2015年9月收治的丙型肝炎失代偿期肝硬化100例患者临床资料进行回顾性分析，由小剂量干扰素逐渐加量行PEG-IFNα-2a或PEG-IFNα-2b与利巴韦林联合治疗，对患者病毒学的应答情况进行评估，包括复发、SVR与无应答。结果 SVR组肝功能失代偿率14.29%(5/35)均比复发组31.25%(10/32)与无应答组78.79%(26/33)低，且复发组、SVR组血小板计数均升高(P<0.05)。结论丙型肝炎失代偿期肝硬化患者采用小剂量干扰素逐渐加量与利巴韦林联合治疗可取得良好临床结局。